Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Pharmacokinetics and Safety Between "BR3006" and Co-administration of "BR3006A", "BR3006B", and "BR3006C" in Healthy Adult Volunteers (Fasting)
Sponsor: Boryung Pharmaceutical Co., Ltd
Summary
This was an open-label, randomized, fasting, single-dose, 2-sequence, 2-period crossover study to evaluate the pharmacokinetics and safety between single oral administration of "BR3006" and co-administration of "BR3006A", "BR3006B," and "BR3006C" in healthy adult volunteers.
Official title: An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 2-period Crossover Study to Evaluate the Pharmacokinetics and Safety Between Single Oral Administration of "BR3006" and Co-administration of "BR3006A", "BR3006B" and "BR3006C" in Healthy Adult Volunteers
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
52
Start Date
2025-07-03
Completion Date
2026-07-03
Last Updated
2025-07-24
Healthy Volunteers
Yes
Conditions
Interventions
Dapagliflozin 10 mg/Pioglitazone 30 mg/Metformin HCl 1000 mg
Orally administered once per day
Dapagliflozin 10 mg
Orally administered once per day
Pioglitazone 30 mg
Orally administered once per day
Metformin HCl 1000 mg
Orally administered once per day
Locations (1)
H Plus Yangji Hospital
Seoul, Gwanak-gu, South Korea